stockrow
Friday 6 November 2026
Export TLX’s income statement to Excel — free account
Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited’s revenue for fiscal 2025 (year ended December 2025) was $803.8 million, up 55.6% from fiscal 2024.
9.64
0.22
+2.34%
Follow TLX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 334 | 517 | 804 | — | +55.2% | 49,732 | 51,794 | 54,653 | +308.2% | |
| Gross margin, % | — | — | — | — | — | — | — | 62.56 | 65.08 | 53.05 | — | (9.5) pt | ||||||
| EBT | — | — | — | — | — | — | — | 2 | 38 | (5) | — | n/m | ||||||
| EBT margin, % | — | — | — | — | — | — | — | 0.61 | 7.34 | (0.66) | — | (1.3) pt | ||||||
| Net income | — | — | — | — | — | — | — | 2 | 38 | (5) | 32 | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 1.05 | 1.56 | 2.38 | — | +50.8% | |||||
| Earnings | — | — | — | — | — | — | — | 0.01 | 0.10 | (0.02) | — | n/m | ||||||
| Cash flow | — | — | — | — | — | — | — | 0.05 | 0.08 | (0.05) | 0.00 | n/m | ||||||
| Capex | — | — | — | — | — | — | — | (0.02) | (0.07) | (0.13) | 0.00 | +140.0% | ||||||
| Free cash flow | — | — | — | — | — | — | — | 0.03 | 0.02 | (0.18) | 0.00 | n/m | ||||||
| Book value | — | — | — | — | — | — | — | 0.31 | 1.07 | 1.23 | 0.00 | +99.1% | ||||||
| Shares, m | — | — | — | — | — | — | — | 319 | 331 | 338 | — | +2.9% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | — | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| P/B | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| EV/Sales | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| EV/FCF | — | — | — | — | — | — | — | 0.00 | 0.00 | 32.89 | (73.88) | 11.0 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | 16 | 27 | (17) | 52 | n/m | |||||
| Capex | — | — | — | — | — | — | — | (7) | (22) | (44) | (56) | +147.1% | ||||||
| Free cash flow | — | — | — | — | — | — | — | 9 | 5 | (61) | (4) | n/m | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | 45 | 365 | 99 | 246 | +48.4% | |||||
| Net debt | — | — | — | — | — | — | — | (71) | (81) | 320 | 324 | n/m | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | 99 | 353 | 415 | 488 | +104.9% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | 0.00 | 5.57 | (0.68) | 0.00 | (0.7) pt | |||||
| ROIC | — | — | — | — | — | — | — | 23.28 | 12.70 | 2.53 | 0.00 | (20.7) pt | ||||||
| ROE | — | — | — | — | — | — | — | 0.00 | 14.91 | (1.85) | 0.00 | (1.8) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 441 | 554 | 1,184 | — | +63.9% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.76 | 0.93 | 0.68 | — | (5.3%) | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · fundamentals updated 26 Oct 2026
Telix Pharmaceuticals Limited vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| TARS Tarsus Pharmaceuticals, Inc. | $3.3B | — (loss-making) | — (loss-making) | +63.92% (above 0%: growing) | n/m | −144.14% (below 0%: shrinking) | 92.86% | (340.29%) | Compare |
| VKTX Viking Therapeutics, Inc. | $3.3B | — (loss-making) | — | — | n/m | −47.01% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ELVN Enliven Therapeutics, Inc. | $3.3B | — (loss-making) | — | — | n/m | −8.34% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| DYN Dyne Therapeutics, Inc. | $3.2B | — (loss-making) | — | — | n/m | −39.08% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| VRDN Viridian Therapeutics, Inc. | $3.2B | — (loss-making) | — (loss-making) | −63.51% (below 0%: shrinking) | n/m | −9.92% (below 0%: shrinking) | 100.00% | (401.82%) | Compare |
| TLX Telix Pharmaceuticals Limited | $3.2B | — | — | — | — | −44.78% (below 0%: shrinking) | — | — | |
| DNLI Denali Therapeutics Inc. | $3.2B | — (loss-making) | — (loss-making) | −93.96% (below 0%: shrinking) | n/m | −11.83% (below 0%: shrinking) | 98.92% | (712.97%) | Compare |
| CELC Celcuity, Inc. | $3.1B | — (loss-making) | — | — | n/m | −53.27% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| IDYA IDEAYA Biosciences, Inc. | $3.0B | — (loss-making) | — (loss-making) | −95.07% (below 0%: shrinking) | n/m | −165.94% (below 0%: shrinking) | 100.00% | (1,343.80%) | Compare |
| Median of peers | $3.2B | — | — | −78.73% | — | −43.04% | 46.43% | (170.14%) |